The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine

被引:45
|
作者
Davis, MP [1 ]
Homsi, J [1 ]
机构
[1] Cleveland Clin Fdn, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44195 USA
关键词
CYP2D6; palliative medicine; drug metabolism; drug interactions; ethnic differences; pharmacokinetics;
D O I
10.1007/s005200000222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The enzymes in the cytochrome p450 monooxygenase system (CYP) are the major enzymes responsible for metabolizing medications. The CYP2D6 isomer is responsible for metabolizing certain opioids, neuroleptics, antidepressants and cardiac medications. Owing to CYP2D6's low capacity and high affinity it is easily saturated by substrate and/or inhibited, resulting in pharmacokinetic interactions. Polymorphisms of the structural gene are common, leading to wide inter-individual and ethnic differences in drug metabolism. Clinically important drug interactions, which may be anticipated in the palliative medicine population, are reviewed.
引用
收藏
页码:442 / 451
页数:10
相关论文
共 50 条
  • [41] Cytochrome b5 Is a Major Determinant of Human Cytochrome P450 CYP2D6 and CYP3A4 Activity In Vivo
    Henderson, Colin J.
    McLaughlin, Lesley A.
    Scheer, Nico
    Stanley, Lesley A.
    Wolf, C. Roland
    MOLECULAR PHARMACOLOGY, 2015, 87 (04) : 733 - 739
  • [42] In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine:: potent effect on CYP2C19 and CYP2D6
    Ko, JW
    Desta, Z
    Soukhova, NV
    Tracy, T
    Flockhart, DA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (04) : 343 - 351
  • [43] A BAMHI POLYMORPHISM IN THE HUMAN CYTOCHROME-P450 GENE, CYP2D6
    MORIMOTO, Y
    MURAYAMA, N
    KUWANO, A
    YOSHIMURA, O
    KONDO, I
    CLINICAL GENETICS, 1995, 47 (02) : 103 - 104
  • [44] Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6
    Worrall, SF
    Corrigan, M
    High, A
    Starr, D
    Matthias, C
    Wolf, CR
    Jones, PW
    Hand, P
    Gilford, J
    Farrell, WE
    Hoban, P
    Fryer, AA
    Strange, RC
    PHARMACOGENETICS, 1998, 8 (05): : 433 - 439
  • [45] Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug
    Berger, Benjamin
    Bachmann, Fabio
    Duthaler, Urs
    Krahenbuhl, Stephan
    Haschke, Manuel
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [46] Allosteric effects of cytochrome P450 reductase on cytochrome P450 2D6
    Roberts, GCK
    Modi, S
    Gilham, DE
    Sutcliffe, MJ
    Lian, LY
    Primrose, WU
    Wolf, CR
    FASEB JOURNAL, 1997, 11 (09): : A789 - A789
  • [47] Genetic Transmission of Cytochrome P450 2D6 (CYP2D6) Ultrarapid Metabolism: Implications for Breastfeeding Women taking Codeine
    Madadi, Parvaz
    Ciszkowski, Catherine
    Gaedigk, Andrea
    Leeder, J. Steven
    Teitelbaum, Ronni
    Chitayat, David
    Koren, Gideon
    CURRENT DRUG SAFETY, 2011, 6 (01) : 36 - 39
  • [48] Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)
    Desta, Z
    Kerbusch, T
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (01) : 10 - 20
  • [49] Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results
    Druid, H
    Holmgren, P
    Carlsson, B
    Ahlner, J
    FORENSIC SCIENCE INTERNATIONAL, 1999, 99 (01) : 25 - 34
  • [50] Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR
    Bodin, L
    Beaune, PH
    Loriot, MA
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2005, (03): : 248 - 253